Gainers

• bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million.
• Lakewood-Amedex (NASDAQ:LABT) stock increased by 16.4% to $2.91. The market value of their outstanding shares is at $5.9 million.
• Intelligent Bio Solutions (NASDAQ:INBS) stock increased by 11.25% to $2.67. The company's market cap stands at $7.2 million.
• Enlivex (NASDAQ:ENLV) stock moved upwards by 9.37% to $1.4. The market value of their outstanding shares is at $22.3 million.
• Dogwood Therapeutics (NASDAQ:DWTX) shares moved upwards by 7.74% to $2.78. The company's market cap stands at $87.7 million.
• SS Innovations Intl (NASDAQ:SSII) shares rose 7.03% to $3.65. The company's market cap stands at $683.3 million.

Losers

• CollPlant Biotechnologies (NASDAQ:CLGN) stock decreased by 19.8% to $0.31 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.3 million.
• Vivos Therapeutics (NASDAQ:VVOS) shares fell 17.2% to $0.16. The company's market cap stands at $3.9 million.
• Cadrenal Therapeutics (NASDAQ:CVKD) shares fell 16.89% to $1.45. The company's market cap stands at $6.2 million.
• Invivyd (NASDAQ:IVVD) shares fell 16.23% to $0.8. The market value of their outstanding shares is at $281.3 million.
• Kala Bio (NASDAQ:KALA) shares fell 13.79% to $0.58. The market value of their outstanding shares is at $13.0 million.
• BioXcel Therapeutics (NASDAQ:BTAI) stock decreased by 13.4% to $0.14. The company's market cap stands at $5.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.